Protalix BioTherapeutics Profile

USD 0.01  1.69%

Sale by Yossi Maimon of 109700 shares of Protalix BioTherapeutics

Protalix BioTherapeutics Inc insider trading alert for sale of common stock by Yossi Maimon, VP Chief Financial Officer, on March 6, 2018. This event was filed by Protalix Biotherapeutics with SEC on 2009-10-19. Statement of changes in beneficial ownership - SEC Form 4. Yossi Maimon is currently serves as cfo, vice president treasurer, secretary of Protalix BioTherapeutics [view details]   

Protalix BioTherapeutics Summary

Protalix BioTherapeutics Inc (PLX) is traded on American Stock Exchange in USA. It is located in ISRAEL and employs 232 people. Protalix BioTherapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Micro-Cap' category with total capitalization of 93.35 M. Protalix BioTherapeutics Inc runs under Healthcare sector within Pharmaceutical Products industry. This company has 145.57 M outstanding shares of which 0 shares are at this time shorted by investors with about 0.0 days to cover shorted positions. PROTALIX BIOTHERA has about 33.48 M in cash with (34.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.24.
Check Protalix BioTherapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Protalix BioTherapeutics Inc Income Statement Over Time

Net Income    Revenues    

Key Fundamentals

Protalix BioTherapeutics Against Markets

Current Ratings

Protalix BioTherapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 48% 
Equity ratings for Protalix BioTherapeutics Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Protalix BioTherapeutics operates under Biotechnology classification in USA and traded on American Stock Exchange exchange. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameProtalix BioTherapeutics Inc
CEO and President and DirectorMoshe ManorView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
RegionNorth America
Business Address2 Snunit Street
Foreign Associate  Israel
ExchangeAmerican Stock Exchange
CIK Number01006281.0
IndustryPharmaceutical Products
Contact Number972 4 988 9488
CurrencyUSD - US Dollar


Protalix BioTherapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
2.6Strong Buy2Odds
Protalix BioTherapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Protalix BioTherapeutics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Protalix BioTherapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.11March 14, 2017
Protalix BioTherapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Protalix BioTherapeutics Corporate Directors
Roger Kornberg Independent Director, Ph.D
Amos BarShalev Independent Director, MBA
Aharon Schwartz Independent Director, Ph.D